Another monoclonal antibody belonging to anti-IL-6 drug class, siltuximab, currently approved in multicentric Castleman disease with HIV-negative and human herpesvirus-8 negative, is under investigation for ARDS in COVID-19 patients. Here, IL6 is linked to COVID-19.